Salix Pharmaceuticals Ltd (SLXP) Tops Q2 EPS by 24c

Salix Pharmaceuticals Ltd (NASDAQ: SLXP) reported Q2 EPS of $0.79, $0.24 better than the analyst estimate of $0.55. Revenue for the quarter came in at $181 million versus the consensus estimate of $180.79 million.

For earnings history and earnings-related data on Salix Pharmaceuticals Ltd (SLXP) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance
• Alliance Laundry Holdings Inc. (ALH) Tops Q1 EPS by 6c
• Kolibri Global Energy Inc. (KGEI) Misses Q2 EPS by 2c